Table 2 Incidence and maximum toxicity observed during CapIri-RT treatment (n=36 patients)

From: A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer

  Grade 1 Grade 2 Grade 3 Grade 4
Haematologic
 Leucocytopenia 12 7 7 2
 Thrombocytopenia 2
 Anaemia 23 9
Gastrointestinal
 Nausea/vomiting 9 10 2
 Mucositis/stomatitis 2
 Diarrhoea 13 15 4
 Proctitis 11 4
 Abdomial cramping 6 4
Laboratory
 Hyperbilirubinaemie 2 1
 ALAT/ASAT elevation 3 3 1
 Creatinine elevation 3
Skin
 Hand-foot skin reaction 3
 Alopecia 5
 Radiation dermatits 12 7
Other
 Fatigue 11 6 1
 Cholinergic syndrome 2
  1. CTC, common toxicity criteria; NCI, National Cancer Institute.
  2. Adverse events are graded according to CTC of the NCI version 2.0.